Virtus Biotech Clinical Trials ETF
12 hedge funds and large institutions have $4.08M invested in Virtus Biotech Clinical Trials ETF in 2025 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 1 closing their positions.
138% more capital invested
Capital invested by funds: $1.71M → $4.08M (+$2.37M)
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
9% more funds holding
Funds holding: 11 → 12 (+1)
6.89% more ownership
Funds ownership: 16.13% → 23.02% (+6.9%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$758K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$535K |
| 3 |
MCP
Militia Capital Partners
Las Vegas,
Nevada
|
+$237K |
| 4 |
Simplex Trading
Chicago,
Illinois
|
+$83.5K |
| 5 |
Morgan Stanley
New York
|
+$52.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$253K |
| 2 |
US Bancorp
Minneapolis,
Minnesota
|
-$19.3K |
| 3 |
LPL Financial
San Diego,
California
|
-$821 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
MCP
1
Militia Capital Partners
Las Vegas,
Nevada
| $1.46M | +$237K | +10,400 | +24% |
|
|
2
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $944K | +$535K | +23,458 | +211% |
|
|
3
Jane Street
New York
| $907K | +$758K | +33,227 | New |
|
|
4
LPL Financial
San Diego,
California
| $340K | -$821 | -36 | -0.3% |
|
|
5
Morgan Stanley
New York
| $293K | +$52.1K | +2,285 | +27% |
|
|
6
Simplex Trading
Chicago,
Illinois
| $99K | +$83.5K | +3,661 | New |
|
|
DWS
7
Dynamic Wealth Strategies
Granite Bay,
California
| $21.9K | – | – | – |
|
8
Osaic Holdings
Scottsdale,
Arizona
| $8.27K | – | – | – |
|
|
9
UBS Group
Zurich,
Switzerland
| $3.36K | -$253K | -11,093 | -99% |
|
|
FDCDDQ
10
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| $3K | – | – | – |
|
|
AF
11
Allworth Financial
Folsom,
California
| $273 | – | – | – |
|
|
NA
12
NewEdge Advisors
New Orleans,
Louisiana
| $136 | – | – | – |
|
|
13
US Bancorp
Minneapolis,
Minnesota
| – | -$19.3K | -1,000 | Closed |
|
BBC Hedge Fund Activity: Q3 2025 in Review
12 of the 7,619 institutional investors tracked by Wall St. Rank reported a position in Virtus Biotech Clinical Trials ETF (BBC) for Q3 2025, worth a combined $4.08M — up 138% from $1.71M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new BBC positions and 1 closed out — a net gain of 1 holder — while 3 added to existing stakes and 2 trimmed.
The largest buyer was Jane Street, opening a new position worth an estimated $758K. The largest seller was UBS Group, cutting an estimated $253K.
- 12 institutional investors held Virtus Biotech Clinical Trials ETF (BBC) as of Q3 2025, up from 11 in Q2 2025.
- Funds reported $4.08M of Virtus Biotech Clinical Trials ETF stock for Q3 2025, up 138% quarter-over-quarter.
- 2 funds opened new Virtus Biotech Clinical Trials ETF positions in Q3 2025 and 1 closed out, a net change of +1 holder.
- The largest Virtus Biotech Clinical Trials ETF buyer in Q3 2025 was Jane Street, an estimated $758K added.
- The largest Virtus Biotech Clinical Trials ETF seller in Q3 2025 was UBS Group, an estimated $253K sold.
Based on aggregated 13F filings for Q3 2025.